Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William L Herring

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Vaccine|December 22, 2021
Clinical and economic outcomes associated with respiratory syncytial virus vaccination in older adults in the United StatesWilliam L Herring, Yuanhui Zhang, Vivek Shinde, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 2, 2024
New IPECAD Open-Source Model Framework for the Health Technology Assessment of Early Alzheimer's Disease Treatment: Development and Use CasesRon Handels, William L Herring, Sabine Grimm, et al.
Vaccines|January 22, 2024
Going Forward: Potential Impact of Protein-Based COVID-19 Vaccination Coverage on Population Outcomes and Costs in the United StatesKyle Paret, Hadi Beyhaghi, William L Herring, et al.
Journal of Comparative Effectiveness Research|November 1, 2022
Evaluation of emerging NASH therapies: the impact of treatment efficacy profiles on long-term health outcomesWilliam L Herring, Ian Gopal Gould, Villum Wittrup-Jensen, et al.
Neurology and Therapy|August 24, 2021
Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer's DiseaseWilliam L Herring, Ian Gopal Gould, Howard Fillit, et al.
Neurology and Therapy|July 3, 2025
Societal Costs and Efficiency of Subcutaneous versus Intravenous Lecanemab in Early Alzheimer's Disease: A U.S. Cost Comparison ModelAmir Abbas Tahami Monfared, Stephanie Barrows, Lindsey Fox, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|November 28, 2022
Cost-Effectiveness of Respiratory Syncytial Virus Preventive Interventions in Children: A Model Comparison StudyXiao Li, David Hodgson, Julien Flaig, et al.
Mayo Clinic Proceedings. Innovations, Quality & Outcomes|July 1, 2021
Estimated Public Health Impact of the Recombinant Zoster VaccineBrandon J Patterson, Philip O Buck, Desmond Curran, et al.
Journal of Internal Medicine|December 15, 2023
People get ready! A new generation of Alzheimer's therapies may require new ways to deliver and pay for healthcareKarin Wahlberg, Bengt Winblad, Amanda Cole, et al.
Journal of Medical Economics|July 10, 2025
Use of patient-reported outcome measures in cost-effectiveness models informing health technology assessments of non-oncology treatments: a reviewOlivia M Dong, Na'ngono Manga, Yue Zhong, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Vaccine|December 22, 2021
Clinical and economic outcomes associated with respiratory syncytial virus vaccination in older adults in the United StatesWilliam L Herring, Yuanhui Zhang, Vivek Shinde, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|August 2, 2024
New IPECAD Open-Source Model Framework for the Health Technology Assessment of Early Alzheimer's Disease Treatment: Development and Use CasesRon Handels, William L Herring, Sabine Grimm, et al.
Vaccines|January 22, 2024
Going Forward: Potential Impact of Protein-Based COVID-19 Vaccination Coverage on Population Outcomes and Costs in the United StatesKyle Paret, Hadi Beyhaghi, William L Herring, et al.
Journal of Comparative Effectiveness Research|November 1, 2022
Evaluation of emerging NASH therapies: the impact of treatment efficacy profiles on long-term health outcomesWilliam L Herring, Ian Gopal Gould, Villum Wittrup-Jensen, et al.
Neurology and Therapy|August 24, 2021
Predicted Lifetime Health Outcomes for Aducanumab in Patients with Early Alzheimer's DiseaseWilliam L Herring, Ian Gopal Gould, Howard Fillit, et al.
Neurology and Therapy|July 3, 2025
Societal Costs and Efficiency of Subcutaneous versus Intravenous Lecanemab in Early Alzheimer's Disease: A U.S. Cost Comparison ModelAmir Abbas Tahami Monfared, Stephanie Barrows, Lindsey Fox, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|November 28, 2022
Cost-Effectiveness of Respiratory Syncytial Virus Preventive Interventions in Children: A Model Comparison StudyXiao Li, David Hodgson, Julien Flaig, et al.
Mayo Clinic Proceedings. Innovations, Quality & Outcomes|July 1, 2021
Estimated Public Health Impact of the Recombinant Zoster VaccineBrandon J Patterson, Philip O Buck, Desmond Curran, et al.
Journal of Internal Medicine|December 15, 2023
People get ready! A new generation of Alzheimer's therapies may require new ways to deliver and pay for healthcareKarin Wahlberg, Bengt Winblad, Amanda Cole, et al.
Journal of Medical Economics|July 10, 2025
Use of patient-reported outcome measures in cost-effectiveness models informing health technology assessments of non-oncology treatments: a reviewOlivia M Dong, Na'ngono Manga, Yue Zhong, et al.
Pageof 2